FDA panel backs Janssen's fast-acting depression treatment

A lack of available treatment options swayed a 14-2 panel vote in favor of recommending approval of intranasal Spravato esketamine (formerly JNJ-54135419) from Janssen Pharmaceuticals Inc. to treat patients with treatment-resistant depression. If approved, Spravato would provide patients that have

Read the full 401 word article

User Sign In